Moleculin reports MIRACLE AML trial enrollment at 78% of 45-subject interim target

Moleculin Biotech, Inc.

Enrollment increased to 78% of target for first interim unblinding (up from 60% in Nov).
First unblinding will involve 45 subjects; treatment completion expected Q1 2026.
Consented subjects across seven countries; recruitment ongoing beyond the 78% mark.
Part A of trial (90 subjects) expected to complete enrollment in H1 2026.
Blinded response activity tracking within expected range per CEO commentary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.